



T R A N S F O R M

pharmaceuticals, inc.

For more information, please contact:

TransForm Pharmaceuticals, Inc.  
Scott Requadt  
781/674-7850

Noonan Russo Presence  
Robert Stanislaro  
212/845-4268

## **TRANSFORM ANNOUNCES SUCCESS IN COLLABORATION WITH ROCHE**

**Lexington, MA, August 5, 2003** – TransForm Pharmaceuticals, Inc. (TransForm) announced today that, in a collaborative effort with Roche, its scientists have succeeded in making the first crystalline form of a new Roche development compound. The findings will assist Roche in advancing the compound into clinical development, and entitle TransForm to a milestone payment under the collaboration.

Under the terms of the collaboration, TransForm receives upfront research funding and success-based milestones from Roche for conducting comprehensive crystallization studies on development-stage Roche compounds.

“We are pleased to have been able to demonstrate our unique capabilities by adding value to this Roche development project,” stated Colin R. Gardner, Ph.D., Chief Scientific Officer for TransForm. “Our success in this challenging project exemplifies the power of combining our expertise in solid-state chemistry with our capabilities in informatics and crystal engineering and our proprietary, high throughput crystallization platform, CrystalMax™,” continued Gardner.

Finding a pharmaceutically acceptable, crystalline form of a drug candidate is generally considered a necessary prerequisite for its development, both to ensure purity and to maximize the likelihood of the compound performing predictably in the formulation. An increasing number of compounds being discovered by the pharmaceutical industry are novel in structure and resistant to crystallization. The ability to crystallize such compounds rapidly can therefore have a significant impact on R&D efficiency, as well as the commercial viability of those product candidates.

Using TransForm's CrystalMax™ technology, coupled with the data mining power of its informatics platforms, TransForm scientists perform several thousand "smart" crystallization experiments on small amounts of drug compounds, employing a broad diversity of solvent combinations, additives and process modes, all within a matter of a month or two. This distinctive set of capabilities enables TransForm to rapidly find innovative approaches and solutions to challenging R&D pharmaceuticals problems, such as compounds that resist crystallization, are highly polymorphic, or are poorly soluble in their original form.

### **About TransForm**

TransForm Pharmaceuticals is reinventing the pharmaceutical industry's approach to form and formulation, with a novel set of high-throughput, automated platform technologies, powered by state-of-the-art informatics and a scientific and managerial team with deep experience in pharmaceuticals. It uses these capabilities to optimize drug form and/or formulations, and increase the clinical and commercial value of pharmaceutical products, across the entire pharmaceutical value chain. In research and development, TransForm is working with partners such as Alza Corporation and Lilly, to help them make better candidate selection decisions, and reduce attrition and development time and cost. For later stage and marketed products, TransForm can help partners enhance product life cycle management by rapidly discovering novel forms and/or formulations to potentially improve bioavailability, broaden intellectual property protection and enable new dosage forms and/or combination products. TransForm is also using these capabilities to develop its own proprietary product portfolio. TransForm, founded in late 1999 with initial technology from Millennium Pharmaceuticals (NASDAQ:MLNM), is a privately held company located in Lexington, MA. For more information visit our website at [www.transformpharma.com](http://www.transformpharma.com).

#####